In a recent release, Veravas launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin. The new VeraBind Biotin will support diagnostic manufacturers in redeveloping lab assays to be biotin-interference-free.
Biotin is found in over-the-counter multivitamins, prenatal vitamins, and dietary supplements for hair, skin, and nail growth. The use of biotin is steadily increasing worldwide. Taking high-dose biotin supplements can interfere with laboratory assays and cause incorrect test results. Ultimately, this interference can lead to misdiagnosis, inappropriate patient management, and adverse events. Because of the potential harm to patients, the FDA recently issued guidance to in vitro diagnostic device manufacturers to include clear labeling indicating biotin interference levels for clinical laboratories and clinicians to consider when interpreting test results.
VeraTest Biotin and VeraPrep Biotin offer immediate solutions to address biotin interference in existing diagnostic tests. VeraTest Biotin is a digital qualitative test that screens for biotin interference in less than five minutes. VeraPrep Biotin can determine if biotin levels are clinically significant and, using targeted nano magnetic beads, capture and remove biotin from a sample. Proof-of-concept studies demonstrated the ability of these products to rule-in or out biotin interference, determine clinically significant levels, and successfully reduce interfering biotin in patient samples.
Veravas also launched VeraBind Biotin, a proprietary monoclonal antibody that can be used by diagnostic manufacturers to convert existing assays to be biotin-interference free. This antibody retains a high binding affinity to conjugated biotin with a low binding affinity to free biotin, thus eliminating the impact of biotin interference on test results.